Efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops in Treating Dry Eye Disease

Launched by UNIVERSITY OF NAPLES · Nov 2, 2023

Keywords

ClinConnect Summary

In this retrospective study, the investigators have examined the historical therapeutic efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops (HAr® 0.1%) in the treatment of Dry Eye Disease (DED), adhering to good clinical practice principles.

Participants were historically divided into two groups:

* Group X: received Riboflavin-Enhanced Hyaluronic Acid Eye Drops (HAr® 0.1%) (Ribohyal Group).
* Group Y: received standard HA 0.1% eye drops (Control Group).

The historical outcome measures included the retrospective assessments of osmolarity, Tear Break-Up Time (TBUT), corneal staining,...

Gender

ALL

Eligibility criteria

• Inclusion criteria for patient selection included a dry eye history of at least three months, OSDI score ≥ 23, and positivity in at least one eye for one or more of the following diagnostic criteria:
• • Tear Break-Up Time (TBUT) \< 7 seconds
• • Schirmer test I at 5 minutes \< 10 mm
• • Corneal and/or conjunctival fluorescein staining
• • Tear osmolarity \> 308 mOsm/L or a difference of at least 8 mOsm/L between both eyes.
• Exclusion Criteria:
• • Age below 18 years
• • Severe ocular surface affections
• • Unilateral dry eye syndrome
• • Refractive surgery performed within the last six months
• • Eye surgery performed within the last three months
• • Previous herpetic keratitis
• • Signs of active corneal infection
• • Systemic or topical steroid therapy within the last 30 days
• • Topical therapy within the last 14 days
• • Inability to understand the informed consent.